Printer Friendly

e/ -- Intelligent Surgical Lasers, Inc. (NASDAQ: ISLS) announced today promising results from clinical studies conducted at the University of California, San Diego and in Gent, Belgium using the recently introduced Eye Laser System to treat myopia (nearsightedness) and hyperopia (farsightedness), according to

 Human clinical trials demonstrated the Eye Laser System's ability to affect changes in corneal curvature using a new technique called intrastromal ablation. This approach is designed to eliminate the pain and many of the side effects associated with traditional surgical or laser procedures.
 "The Eye Laser System was developed to treat refractive disorders such as nearsightedness, farsightedness and astigmatism using intrastromal ablation in which tissue is ablated or 'vaporized' within the cornea," Gisel said.
 The clinical results demonstrate the Eye Laser's ability to achieve predictable refractive corrections. Patients treated at both centers independently showed between one and two diopters of refractive correction based on predetermined system parameters.
 "This is very encouraging in that the desired refractive corrections were achieved and have remained stable over a follow-up period up to two months," Gisel added. "Unlike with currently used laser systems, patients can be retreated to affect even greater refractive changes."
 The laser system used in the Gent, Belgium clinical trials is the first Eye Laser System sold outside the United States. In March 1993, ISL announced that it had filed Investigational Device Exemptions (IDEs) with the U.S. Food and Drug Administration for use of the Eye Laser System in treating myopia and for the Model 2001 to treat glaucoma.
 Intelligent Surgical Lasers, Inc. (ISL) is a development stage biomedical company which designs and manufactures innovative, technologically advanced laser systems for the treatment of a broad range of ophthalmic disorders. Many of these disorders are difficult or impossible to treat with current lasers or traditional medical instruments. Founded in 1987, ISL completed a public offering in September 1992. (NASDAQ: ISLS).
 -0- 4/19/93
 /CONTACT: Heinz Gisel, chairman and CEO of ISL, Inc., 619-552-6700, or Linda Seaton of Keatinge/Seaton Communications, 619-625-2100, for ISL/
 (ISLS)


CO: Intelligent Surgical Lasers, Inc. ST: California IN: MTC SU:

LR-SB -- NY029 -- 7202 04/19/93 09:15 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 19, 1993
Words:313
Previous Article:NEW STRUMMER'S FRUITED RUM ENTERS U.S. TEST MARKETS IN APRIL; AUTHENTIC JAMAICAN RUM FROM MONSIEUR HENRI TO 'STIR UP' SPECIALTY RUM CATEGORY
Next Article:CHASE REPORTS FIRST QUARTER 1993 NET INCOME OF $153M PLANS DISPOSITION OF $2.0B OF REAL ESTATE ASSETS ANNOUNCES COMMON STOCK OFFERING OF $750M
Topics:


Related Articles
SUMMIT TECHNOLOGY RECEIVES IDE FROM FDA FOR TREATMENT OF ASTIGMATISM WITH HOLMIUM LASER SYSTEM
SUMMIT TECHNOLOGY ANNOUNCES FDA APPROVAL TO BEGIN SECOND PHASE OF U.S. CLINICAL TRIALS USING HOLMIUM LASER FOR TREATMENT OF FARSIGHTEDNESS
SUMMIT TECHNOLOGY ANNOUNCES FDA APPROVAL TO BEGIN SECOND PHASE OF U.S. CLINICAL TRIALS USING HOLMIUM LASER FOR TREATMENT OF FARSIGHTEDNESS
SUMMIT TECHNOLOGY RECEIVES TWO FDA APPROVALS TO BEGIN PHASE III CLINICAL TRIALS USING HOLMIUM LASER FOR TREATMENT OF FARSIGHTEDNESS & ASTIGMATISM
VISX RECEIVES FDA APPROVAL FOR ITS EXCIMER LASER SYSTEM; CONSUMERS NOW HAVE A CHOICE BETWEEN FDA-APPROVED SYSTEMS
Summit Receives FDA Approval to Expand Farsightedness Clinical Trials with Apex Plus Laser
VISX Expands FDA Clinical Trials For Hyperopia
Take a Closer Look ... Wilmer Eye Institute Seeking Patients to Participate in Clinical Trials of Laser Vision Correction for Farsightedness
Take A Closer Look ... Kraff Eye Institute Seeking Patients to Participate In Clinical Trails of Laser Vision Correction for Farsightedness

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters